News

HSCT Seen as Superior to Current Therapies for Severe, Progressive Sclerosis

Autologous hematopoietic stem cell transplantation (HSCT), evaluated in 18 people with rapidly progressing systemic sclerosis, found the experimental therapy superior to standard treatments for the disease for this patient population. The retrospective report detailing these findings, “Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive…

New Guidelines Aim to Advance Plasma Exchange as Scleroderma Therapy

The Scleroderma Education Project recently released guidelines for patients and doctors wishing to know more about therapeutic plasma exchange (TPE) as a treatment option for limited scleroderma. The guidelines are designed to facilitate data collection to support the launch of a randomized clinical trial, and follow the same setup as…